The American Lung Association condemned the recently announced acquisition of Vectura by cigarette maker Philip Morris (NYSE:PM). Earlier this month, Philip Morris announced that it agreed to acquire inhaled drug delivery technology developer Vectura for $1.2 billion. In response to the acquisition, American Lung Association president & CEO Harold Wimmer and American Thoracic Society president Dr. Lynn […]
Mergers & Acquisitions
Eli Lilly acquires glucose-sensing insulin developer Protomer Technologies
Eli Lilly (NYSE:LLY) announced today that it acquired peptide- and protein-engineering platform developer Protomer Technologies. Pasadena, Calif.-based Protomer Technologies develops next-generation protein therapeutics designed to identify and synthesize molecules that can sense glucose or other endogenous modulators of protein activity. Indianapolis-based Eli Lilly said in a news release that the potential value of the transaction […]
Cigarette maker spending $1.2 billion on company with inhaled medical therapies
Philip Morris (NYSE:PM) announced today that it agreed to acquire inhaled drug delivery technology developer Vectura for $1.2 billion. New York–based Philip Morris agreed with the board of Vectura Group on the all-cash, recommended offer under which Vectura shareholders would be entitled to receive $2.07 per share (150 pence), representing a 46% premium to the […]
Charles River Laboratories completes $292.5M Vigene acquisition
Charles River Laboratories (NYSE:CRL) announced that it completed a $292.5 million acquisition of Vigene Biosciences. Rockville, Md.-based Vigene, a gene therapy contract development and manufacturing organization (CDMO), develops viral vector-based gene delivery systems, with a primary area of expertise in CGMP viral vector manufacturing for gene therapies and gene-modified cell therapies. According to a news […]
Pear Therapeutics to go public via merger with SPAC
Prescription digital therapeutics pioneer Pear Therapeutics announced today that it will go public by merging with a SPAC called Thimble Point Acquisition Corp. Boston-based Pear Therapeutics’ combination with the special purpose acquisition company (SPAC), whose management team is associated with the Pritzker Vlock Family Office, will result in a combined company named Pear Holdings Corp. […]
Carbon Health acquires Steady Health and its diabetes platform
Carbon Health announced today that it acquired Steady Health and its platform for using continuous glucose monitoring to personalize diabetes care. San Francisco–based Carbon Health said in a news release that the acquisition accelerates its rollout of a new primary care model designed to integrate its clinic footprint with virtual and hardware-enabled capabilities to create […]
NeuroRx completes merger with SPAC, starts trading on Nasdaq
NeuroRx announced today that it commenced trading on the Nasdaq market following its merger with Big Rock Partners Acquisition Corp. The combined business entity will be known as NRx Pharmaceuticals and will trade on the Nasdaq market under the NRXP ticker, according to a news release. Radnor, Pa.-based NRx develops Zyesami, a synthetic form of […]
DarioHealth acquires PsyInnovations for $30M
DarioHealth announced that it entered into an agreement to acquire digital health company PsyInnovations for up to $30 million. PsyInnovations develops the wayForward behavioral digital health platform with AI-enabled screening to triage and navigate members to specific interventions, digital cognitive behavioral therapy (CBT), self-directed care, expert coaching and access to in-person and telehealth provider visits, according […]
Ginkgo Bioworks buys Dutch microbe company ahead of going public
Ginkgo Bioworks announced today that it agreed to acquire fungal platform technology developer Dutch DNA ahead of going public. Last week, the Boston-based cell programming platform developer announced that it was combining with Soaring Eagle Acquisition Corp. to go public. The SPAC values Ginkgo at $15 billion and is expected to provide up to $2.5 […]
Amgen completes $1.9B acquisition of Five Prime Therapeutics
Amgen (NSDQ:AMGN) announced today that it successfully completed its $1.9 billion acquisition of Five Prime Therapeutics (NSDQ:FPRX). Thousand Oaks, Calif.-based Amgen has officially acquired South San Francisco-based Five Prime for $38 per share in cash, reaching an equity value of approximately $1.9 billion. The acquisition was initially announced on March 4, 2021. As of the […]
